Future of Celera's KIF6 Test Unclear Amid FDA Rejection, Pending Quest Acquisition
April 27, 2011
Future of Celera's KIF6 Test Unclear Amid FDA Rejection, Pending Quest Acquisition
Quest, which plans to acquire Celera by the end of the month, could provide the financial backing to conduct prospective studies for the KIF6 test, or it could decide to scrap the KIF6 program altogether.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Authors of Large Meta-Analysis Predict End of KIF6 Test, but Celera Calls Study Flawed
October 13, 2010 / Pharmacogenomics Reporter - Medco Study Suggests Genetic Testing Improves Patient Compliance with Statins
October 19, 2011 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Integrated Diagnostics Secures Additional $10M to Prep for 2013 Launch of Lung Cancer Dx
February 24, 2012 / ProteoMonitor - FDA Tells Celera KIF6 Test Unapprovable Without Changes
April 21, 2011 / GenomeWeb Daily News